Clostridioides difficile infection (CDI) recurrences are associated with substantial clinical and economic burden including high mortality and high hospitalization cost. We analyzed recently available 100% Medicare Fee-for-Service (FFS) claims to assess recurrence and identify risk factors for patients experiencing 1, 2, and 3+ recurrences of CDI (rCDI) to inform CDI patient management.